News >

Lead Investigator Shares Early Data With Ibrutinib Maintenance in MCL

Brandon Scalea
Published: Tuesday, Jun 18, 2019

Reem Karmali, MD

Reem Karmali, MD
Ibrutinib (Imbruvica) maintenance therapy appeared to be feasible and safe in patients with mantle cell lymphoma (MCL) who respond to frontline induction therapy with or without autologous stem cell transplant (ASCT), said Reem Karmali, MD, MS.

In a study presented at the 2019 ASCO Annual Meeting, 36 patients with advanced stage (n = 28) and extranodal disease (n = 9), were included. Fifty percent of these patients had low-risk MIPI score (n = 18), while 19% (n = 7) and 31% (n = 11) had intermediate- and high-risk MIPI scores, respectively.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x